-
Mashup Score: 1Alpha-1 Adrenergic Antagonists Sensitize Neuroblastoma to Therapeutic Differentiation - 8 month(s) ago
Targeting α-adrenergic receptors synergizes with isotretinoin to suppress growth and to promote differentiation of neuroblastoma, revealing a combinatorial approach for more effective management of the disease and prevention of relapse.
Source: aacrjournals.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Wolters Kluwer Health - 11 month(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Researchers conducted a study showing #lorlatinib is safe and effective in treating high-risk #neuroblastoma in children, adolescents, and adults with relapsed or refractory ALK-mutated or ALK-amplified neuroblastoma. @WinshipAtEmory @ChildrensPhila https://t.co/GrLecz21tH https://t.co/B8k0VgPe4F
-
-
Mashup Score: 0RIST Improves PFS in Relapsed/Refractory Neuroblastoma - 11 month(s) ago
Rapamycin, dasatinib, irinotecan, and temozolomide (RIST) improves progression-free survival vs irinotecan and temozolomide in relapsed/refractory neuroblastoma, a phase 2 trial suggests.
Source: Cancer Therapy AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Combination treatment with RIST improves PFS in children and young adults with R/R #neuroblastoma, when compared to irinotecan plus temozolomide. Presented at @ASCO #ASCO23. https://t.co/T1ZzzmaHeK #EndocrineCancer #PedOnc
-
-
Mashup Score: 2Wolters Kluwer Health - 11 month(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Researchers conducted a study showing #lorlatinib is safe and effective in treating high-risk #neuroblastoma in children, adolescents, and adults with relapsed or refractory ALK-mutated or ALK-amplified neuroblastoma. @WinshipAtEmory @ChildrensPhila https://t.co/GrLecz21tH https://t.co/0vcaMvUnUK
-
-
Mashup Score: 0Survival in Patients With Neuroblastoma on Reduced Therapy as a Result of Change in COG Risk Stratification - The ASCO Post - 11 month(s) ago
In an analysis recently reported in the Journal of Clinical Oncology,1 Bender et al found that “excellent” survival outcomes were achieved in patients receiving reduced treatment for neuroblastoma as a result of reassignment to intermediate risk from high risk based on a change in the minimum age for high-risk disease classification in Children’s Oncology Group (COG) risk stratification. As…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Survival in Patients With Neuroblastoma on Reduced Therapy as a Result of Change in COG Risk Stratification https://t.co/JuYwMhqDZp #btsm #neuroblastoma #oncology
-
-
Mashup Score: 0Neuroblastoma Survivors Report Neurocognitive Impairment, Failure to Reach Milestones - 11 month(s) ago
Survivors of childhood neuroblastoma have neurocognitive impairments that affect their ability to reach adult milestones, a study suggests.
Source: Cancer Therapy AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Survivors of childhood #neuroblastoma have neurocognitive impairments that affect their ability to reach adult milestones. Published in @JournalCancer. https://t.co/uApwVOXMA7 #PancreaticCancer #EndocrineCancer
-
-
Mashup Score: 7Reversible transitions between noradrenergic and mesenchymal tumor identities define cell plasticity in neuroblastoma - Nature Communications - 11 month(s) ago
Noradrenergic and mesenchymal cell states have been proposed in neuroblastoma, but their contributions to the tumour are not clearly understood. Here, the authors used in vitro and in vivo models, as well as single-cell RNA-seq, to characterise noradrenergic and mesenchymal cells and their phenotypic plasticity in neuroblastoma.
Source: NatureCategories: General Medicine News, Latest HeadlinesTweet-
Recently published #CancerResearch: Thirant et al. use in vitro and in vivo models and #scRNA-seq to characterise noradrenergic and mesenchymal cells and their phenotypic plasticity in #neuroblastoma @natrescancer https://t.co/c7rQMyFv4d
-
-
Mashup Score: 0JCI - Genetic predisposition to neuroblastoma results from a regulatory polymorphism that promotes the adrenergic cell state - 12 month(s) ago
Abstract Childhood neuroblastomas exhibit plasticity between an undifferentiated neural crest–like mesenchymal cell state and a more differentiated sympathetic adrenergic cell state. These cell states are governed by autoregulatory transcriptional loops called core regulatory circuitries (CRCs), which drive the early development of sympathetic neuronal progenitors from migratory neural crest…
Source: www.jci.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Out today in @jclinicalinvest. How does a single SNP in an intron of LMO1 control susceptibility to #neuroblastoma? @NWeichertLeahey wondered and after many years of work, now we know! @DFBC_PedCare @StJudeResearch https://t.co/xDRwsJJAMw
-
-
Mashup Score: 0Investigational CAR T Product GD2-CART01 Displays Safety and Efficacy in Pediatric Neuroblastoma - 12 month(s) ago
Treatment with the third-generation CAR T-cell agent GD2-CART01 was safe and feasible for patients aged 1 to 25 years with relapsed or refractory high-risk neuroblastoma.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Treatment with the third-generation CAR T-cell agent GD2-CART01 was safe and feasible for patients aged 1 to 25 years with relapsed or refractory high-risk neuroblastoma. #oncology #nursing #neuroblastoma #CART #pediatriccancer https://t.co/6Jwm2W0bSj https://t.co/tlWgf9pW43
-
-
Mashup Score: 0Investigational CAR T Product GD2-CART01 Displays Safety and Efficacy in Pediatric Neuroblastoma - 1 year(s) ago
Treatment with the third-generation CAR T-cell agent GD2-CART01 was safe and feasible for patients aged 1 to 25 years with relapsed or refractory high-risk neuroblastoma.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Treatment with the third-generation CAR T-cell agent GD2-CART01 was safe and feasible for patients aged 1 to 25 years with relapsed or refractory high-risk neuroblastoma. #oncology #nursing #neuroblastoma #CART #pediatriccancer https://t.co/blFM0ny82Q
-
From the most recent issue— Alpha-1 Adrenergic Antagonists Sensitize #Neuroblastoma to Therapeutic Differentiation, by Broso et al. https://t.co/iC37x19XkS @UniTrento https://t.co/Mb5a1jrJy2